Bicycle Therapeutics (BCYC) EBITDA (2018 - 2026)

Bicycle Therapeutics has reported EBITDA for 9 years, with the latest figure at -$62.6 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA changed 0.43% year-over-year to -$62.6 million; the trailing twelve-month figure through Mar 2026 stood at -$222.8 million (down 9.29% YoY), and the FY2025 full-year result was -$222.6 million, down 32.8% from the prior year.
• EBITDA for Q1 2026 stood at -$62.6 million, down from -$20.2 million in the prior quarter.
• The five-year high for EBITDA was -$20.2 million in Q4 2025, with the low at -$80.9 million in Q2 2025.
• Historically, EBITDA has averaged -$43.8 million across 5 years, with a median of -$43.6 million in 2023.
• The largest YoY upside for EBITDA was 58.42% in 2025 against a maximum downside of 139.41% in 2025.
• Bicycle Therapeutics' EBITDA stood at -$30.1 million in 2022, then tumbled by 76.92% to -$53.3 million in 2023, then increased by 8.89% to -$48.6 million in 2024, then soared by 58.42% to -$20.2 million in 2025, then tumbled by 210.08% to -$62.6 million in 2026.
• The last three EBITDA figures came in at -$62.6 million (Q1 2026), -$20.2 million (Q4 2025), and -$59.2 million (Q3 2025), per Business Quant data.